Roivant Sciences (ROIV) Assets Average (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Assets Average came in at $5.5 billion in Q1 2026, down 2.63% YoY from $5.6 billion in Q1 2025, and up 6.28% on a QoQ basis from $5.1 billion in Q4 2025.
Analysis
Roivant Sciences (ROIV) Assets Average (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Assets Average data on file, last reported at $5.5 billion in Q1 2026.
- Quarterly Assets Average fell 2.63% year-over-year to $5.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 billion (down 2.63% YoY) and the FY2026 annual result came in at $5.5 billion, down 2.63% from the prior year.
- Assets Average advanced to $5.5 billion in Q1 2026, from $5.1 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $7.3 billion in Q1 2024 to a low of $2.1 billion in Q3 2023.
- A 5-year average of $4.4 billion and a median of $5.0 billion in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average dropped 25.14% — and 2024, when it soared 216.49%.
- Tracing ROIV's Assets Average over 5 years: stood at $2.2 billion in 2022, then surged by 112.25% to $4.7 billion in 2023, then gained by 27.94% to $6.0 billion in 2024, then fell by 14.26% to $5.1 billion in 2025, then grew by 6.28% to $5.5 billion in 2026.
- The last three Assets Average figures came in at $5.5 billion (Q1 2026), $5.1 billion (Q4 2025), and $5.0 billion (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.51 Bn |
| Mar 31, 2026 | 5.47 Bn |
| Dec 31, 2025 | 5.14 Bn |
| Sep 30, 2025 | 5.05 Bn |
| Jun 30, 2025 | 5.23 Bn |
| Mar 31, 2025 | 5.61 Bn |
| Dec 31, 2024 | 6.00 Bn |
| Sep 30, 2024 | 6.35 Bn |
| Jun 30, 2024 | 6.86 Bn |
| Mar 31, 2024 | 7.27 Bn |
| Dec 31, 2023 | 4.69 Bn |
| Sep 30, 2023 | 2.10 Bn |
| Jun 30, 2023 | 2.26 Bn |
| Mar 31, 2023 | 2.30 Bn |
| Dec 31, 2022 | 2.21 Bn |
| Sep 30, 2022 | 2.41 Bn |
| Jun 30, 2022 | 2.59 Bn |
| Mar 31, 2022 | 2.69 Bn |
| Dec 31, 2021 | 2.95 Bn |
| Sep 30, 2021 | 2.78 Bn |